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Abnormal thyroid function in peritoneal dialysis patients:
Lots of smoke but no fireThyroid disorders are the second most common endocrine
condition following diabetes mellitus. It is not difficult for
physicians to diagnose and treat patients with overt hypothy-
roidism or hyperthyroidism presenting significant biochemical
derangements and clinical symptoms. In the spectrum of
subclinical thyroid dysfunction and nonthyroidal illness
syndrome (i.e., alterations in thyroid hormones without any
underlying intrinsic thyroid disorder), however, it is not
always an easy task. The interpretation of thyroid functions in
patients with chronic kidney disease (CKD) or end-stage renal
disease (ESRD) is even more complicated by the declination
in glomerular filtration rate (GFR), the difference in dialysis
modalities, and comorbidities.
CKD is a well-known cause of nonthyroidal illness syndrome
and affects all levels of the hypothalamus-pituitary-thyroid
axis. Serum TSH levels are usually normal or elevated in
CKD patients with normal or low free and total T3 and T4
levels.1 Low T3 syndrome is the most frequently observed
thyroid alteration in CKD patients.1 An epidemiological study
using data from NHANES III, indicated a higher prevalence
of hypothyroidism in predialysis CKD patients; it is mainly
subclinical among these patients.2 Furthermore, there was
a graded and increased likelihood of hypothyroidism with
progressively lower GFR.2 These disarrangements are similar
in ESRD patients after the commencement of peritoneal
dialysis (PD) treatment. The major thyroid dysfunctions in
PD patients include subclinical hypothyroidism and low T3
syndrome.3 The clearance of iodide is primarily by glomerular
filtration. Thus, iodide excretion is diminished in advanced
CKD, with subsequent elevation in plasma inorganic iodide
concentration. Increases in total body inorganic iodide can
block thyroid hormone production (the Wolff-Chaikoff effect),
which may explain the high incidence of subclinical hypo-
thyroidism in CKD patients.4 Low T3 levels reflect a dimin-
ished conversion of T4 to T3 in the periphery. Its physiological
significance has been interpreted as an adaptive compensatory
attempt to conserve energy stores by reducing metabolic rate
in diseased states.
Increasing evidence supports the association of subclinical
hypothyroidism with cardiovascular diseases (CVD) and
mortality. Because of the known effects of thyroid hormone,
including modulating heart rate, cardiac contractility, arterial
peripheral resistance and cholesterol metabolism, it is1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.12.001reasonable to predict adverse cardiovascular effects in subclin-
ical hypothyroidism. Recent large, prospective, cohort and
meta-analysis studies have demonstrated that subclinical
hypothyroidism is associated with an increased risk for CVD,
cardiovascular and all-cause mortality.5,6 Moreover, patients
with low T3 levels also had a high risk for acute myocardial
infarction, heart failure and mortality.7,8
CVD is the major cause of mortality among CKD patients.
In line with previous studies in unselected populations, there is
an association between T3 levels and inflammatory markers
including C-reactive protein (CRP), and interleukin 6(IL-6),
nutritional marker (albumin), and cardiac function in CKD
patients.9 Furthermore, the reduction in total T3, but not in
free T3 levels, was associated with increased all-cause and
cardiovascular mortality in euthyroid CKD patients.9 In PD
patients, subclinical hypothyroidism displayed a lower left
ventricular ejection fraction (LVEF) compared to those with
normal TSH levels. Elevated TSH levels were associated with
decreased LVEF10 and low serum free T3 levels were asso-
ciated with arterial stiffness.11 Further investigations showed
an inverse relationship between free T3 levels and CRP and
IL-6, as well as serum albumin levels, in PD patients.12 During
a 2.8-year follow-up, the lower free T3 levels were associated
with a survival disadvantage.12 Several factors, including
malnutrition and intercurrent processes, may be involved in
the reduction of serum T3 in PD patients. The presence of
malnutrition, associated with a reduction of binding protein
synthesis, could reduce plasma total T3 concentration. The
elevated IL-1, IL-6 and TNF-a in PD patients, can mediate
down-regulation of deiodinase, an enzyme responsible for T4-
to-T3 conversion in peripheral tissues.13 It would explain how
chronic inflammation associated with CKD interferes with the
normal process of T3 synthesis from T4.
In this issue of the Journal, Lin et al examined the rela-
tionship between thyroid function and mortality in PD patients
with long dialysis duration.14 The major finding of this study
was the presence of a mild thyroid dysfunction linked to an
increased risk of mortality in long-term PD patients. The result
confirmed previous findings. Why can abnormal thyroid
function predict mortality in long-term PD patients? Abnormal
thyroid function may be part of the pathologic processes
leading to a progressive deterioration of the cardiovascular
system. On the contrary, the hypothesis of an adaptive andhinese Medical Association. All rights reserved.
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has become questionable. Another possible interpretation is
that abnormal thyroid function is a marker of poor health,
which is not causally related to cardiovascular disease. Indeed,
there are more noncardiac deaths among long-term PD
patients. Unlike T3, the relationship between inflammation
and T4 in CKD or PD patients is less defined. The authors first
demonstrated free T4 levels inversely correlated with CRP in
PD patients. It is a tempting idea to replace thyroxine in PD
patients with abnormal thyroid function; however, we still
need to understand the clinical and biochemical implications
of these derangements, before the intervention.
There are some points to be clarified in this study.14 Firstly,
all PD patients were classed as having either an abnormal or
normal thyroid function status based on one blood test; there
was a lack of information about follow-up thyroid function
tests. In a study on hemodialysis patients,4 the multiple
regression analysis showed that total T3 and free T3 were
independently associated with dialysis duration. The authors
should tone down their conclusion regarding the relationship
between thyroid dysfunction and mortality over a relatively
long period using tests obtained at a single point of time.
Moreover, Tang et al15 stated that the diagnosis of hypothy-
roidism in uremic patients cannot be made by clinical or
routine laboratory values and rests on the presence of an
overtly elevated serum TSH concentration. Secondly, labora-
tory data overlap between hypothyroidism and nonthyroidal
illness syndrome, and it is difficult to differentiate them
exactly in PD patients. The term “abnormal thyroid function”
in this article,14 which may include the two different condi-
tions, is nonspecific and heterogonous. It is not biologically
plausible to further explore the possible underlying mecha-
nisms between thyroid hormone and mortality in PD patients.
Although the authors tried to account for variables affecting
mortality in a multivariate analysis, they may not have
accounted for currently known risk factors, like serum
albumin, systolic blood pressure, and smoking status. Finally,
this is a retrospective study on a highly selective PD patient
group, with long dialysis duration. The potential bias inherent
in the study would render the conclusion premature. There-
fore, until further mechanistic studies have been performed,
abnormal thyroid function should be considered as a marker
for survival disadvantage and not an etiological factor in PD
patients. Just as the authors stated, we should be alerted to the
alteration of thyroid function tests in PD patients, and search
for the possible causes of the derangement.
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